|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our purpose was to assess the combination of pretreatment IP-10 levels with IL28B SNPs as predictors of treatment response to pegylated interferon α-2a plus ribavirin in patients infected with genotype 1 hepatitis C virus in China.
|
26470765 |
2016 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Efficacy and tolerance of a 6-month treatment course of daily interferon-alpha 2a for chronic hepatitis C with cirrhosis. The Australian Hepatitis C Study Group.
|
9310930 |
1997 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The objective of this study was to determine the virologic response with consensus interferon or pegylated interferon alpha-2b plus weight-ribavirin in patients chronically infected with HCV genotype 1.
|
17406822 |
2007 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A total of 71 treatment-naive HCV RNA-positive patients with biopsy-confirmed chronic hepatitis, with genotype 2b or 3a, viral load < or = 3 million copies per ml and no cirrhosis were randomized to receive either standard interferon therapy (3 MIU interferon-alpha-2a thrice weekly) for 26 weeks or 6 MIU interferon-alpha-2a daily for 4 weeks (induction group) followed by the standard dose (3 MIU thrice weekly) for 22 weeks.
|
11916198 |
2002 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Forty-two patients chronically infected with HCV (for genotype 1, n = 21; for genotype 6, n = 21) were treated with pegylated interferon alpha-2a (n = 20) or alpha-2b (n = 22) combined with oral ribavirin for 48 weeks.
|
18657036 |
2008 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Prediction of a null response to pegylated interferon α-2b plus ribavirin in patients with high viral load genotype 1b hepatitis C.
|
25071908 |
2014 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon alpha 2a therapy.
|
7636506 |
1995 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The present study sought to confirm the association between HCV and the Delta 32 mutation of the CCR5 gene and to correlate it with the response to therapy with interferon-alpha-2a and ribavirin.
|
12865070 |
2003 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Mutations in the interferon sensitivity-determining region of hepatitis C virus genotype 2a correlate with response to pegylated-interferon-alpha 2a monotherapy.
|
19152412 |
2009 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Ribavirin dose reduction raises relapse rate dose-dependently in genotype 1 patients with hepatitis C responding to pegylated interferon alpha-2b plus ribavirin.
|
19552664 |
2009 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A series of 29 patients undergoing treatment for chronic hepatitis C virus (HCV) genotype 1 infection with pegylated alpha-2a interferon plus ribavirin were studied for patterns of response to antiviral therapy and viral quasispecies evolution.
|
15709027 |
2005 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Co-infected (n = 13) and mono-infected naïve patients (n = 100) with HCV genotype 2/3 were treated with 135 microg pegylated interferon alpha-2a weekly and weight-based ribavirin daily for 24 weeks.
|
20214543 |
2010 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus.
|
14999598 |
2004 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Prevalence of hepatitis C virus genotype 1a in Japan and correlation of mutations in the NS5A region and single-nucleotide polymorphism of interleukin-28B with the response to combination therapy with pegylated-interferon-alpha 2b and ribavirin.
|
22246829 |
2012 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Serum lipids in European chronic HCV genotype 1 patients during and after treatment with pegylated interferon-α-2a and ribavirin.
|
20729742 |
2010 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients.
|
17680654 |
2007 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Emergence of occult minority genotype 2b hepatitis C infection in an HIV-1-co-infected patient treated for genotype 5a HCV infection with 48 weeks of pegylated-interferon-alpha 2b and ribavirin.
|
17631045 |
2007 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We examined the association between IL28B single-nucleotide polymorphism rs12979860, hepatitis C virus (HCV) kinetic, and pegylated interferon alpha-2a pharmacodynamic parameters in HIV/HCV-coinfected patients from South America.
|
21157362 |
2011 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thirty-four patients with recurrent hepatitis C genotype 1b after living-donor liver transplantation received combination therapy with pegylated interferon α-2b and ribavirin.
|
20110853 |
2010 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Plasma samples from HCV genotype 2 or 3-infected patients participating in the NORDynamIC trial (n=382) comparing 12 and 24 weeks of combination treatment with pegylated interferon-α2a and a fixed dose of 800 mg ribavirin daily were analyzed for coreAg.
|
22113307 |
2012 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naïve Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial.
|
19032459 |
2009 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We treated four consenting RT recipients who developed acute de novo HCV infection with a combination of interferon-alpha 2b and ribavirin.
|
14568274 |
2003 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Two hundred and fourteen individuals with genotype 1b HCV-related chronic hepatitis underwent treatment with pegylated (peg)-interferon alpha-2A 180 μg once weekly and ribavirin 1,000-1,200 mg/day; 174 were responders.
|
20652232 |
2010 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A Markov model was developed to estimate costs and quality-adjusted life years (QALYs) comparing between the combination of pegylated interferon alpha 2a or alpha 2b and ribavirin with a usual palliative care for genotype 1 and 6 HCV patients.
|
27492396 |
2016 |
|
Hepatitis C
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Stabilized, opioid-dependent patients with chronic HCV infection (genotype 2 or 3) received pegylated interferon alpha-2a in combination with ribavirin 800 mg/day (Group A) or 400 mg/day (Group B).
|
19291011 |
2009 |